How to Treat Osteoporosis in Octogenarians?

Temel Bulgular & Veri:This study aimed to compare the effectiveness of osteoporosis treatment among individuals older and younger than 80 years of age.

💡

Sonuç & Katkı:Bone mineral density (BMD) changes were similar between the

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: There are few studies investigating the efficacy of anti-osteoporotic drugs in the oldest old. This study aimed to compare the effectiveness of osteoporosis treatment among individuals older and younger than 80 years of age. Materials and Methods: A total of 257 patients with osteoporosis, aged 65 and over, 234 women and 23 men, were included in the study. Sixtyfive of the patients were aged 80 years and older. Seventy-four participants received alendronate, 93 received zoledronic acid, and 90 received denosumab. Dual-energy X-ray absorptiometry scans were performed at baseline and at month 24. Results: The proportion of the participants receiving glucocorticoid was higher in the under 80-age group. Bone mineral density (BMD) changes were similar between the

🔖

Bu Makaleye Atıf Yap

ÇİĞİLOĞLU, A., EFENDİOĞLU, E. M., ÖZTÜRK, Z. A., ÖZTÜRK, E. (2022). How to Treat Osteoporosis in Octogenarians?. European journal of geriatrics and gerontology (Online), Cilt: 4 - Sayı: 2, 114–118. https://ajindex.com/articles/511180

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet 2019;393:364- 376
Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE. Diagnosis and Management of Osteoporosis. Am Fam Physician 2015;92:261-268
Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 2016;374:254-262
Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 2021;16:533
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513-523
Tsukutani Y, Hagino H, Ito Y, Nagashima H. Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis. Osteoporos Int 2015;26:2249-2255
Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 2002;77:334-338
Gardner MJ, Brophy RH, Demetrakopoulos D, Koob J, Hong R, Rana A, Lin JT, Lane JM. Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. J Bone Joint Surg Am 2005;87:3-7
Andrade SE, Majumdar SR, Chan KA, Buist DSM, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 2003;163:2052-2057
Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012;97:1871-1880
Riggs BL, Khosla S, Melton LJ. The type I/type II model for involutional osteoporosis. In:Marcus R, Feldman D, Kelsey J (Eds). 2th edition, Osteoporosis Acad San Diego, 2001, pp 49-57
Rizzoli R, Branco J, Brandi M-L, Boonen S, Bruyère O, Cacoub P, Cooper C, Diez-Perez A, Duder J, Fielding RA, Harvey NC, Hiligsmann M, Kanis JA, Petermans J, Ringe JD, Tsouderos Y, Weinman J, Reginster JY. Manage